ment was not initiated, and repeat blood cultures remained negative.
Case 3. A 70-year-old female from Illinois with rheumatoid arthritis on chemotherapy for breast cancer was admitted to an ED with hypotension and shortness of breath. The patient had leukocytosis but was afebrile. A blood culture demonstrated growth of Gram-positive rods. The patient received no antibacterial therapy, and subsequent blood cultures remained negative.
Twelve of the 14 isolates could be retrieved from a frozen repository and were subcultured at least twice on Columbia SBA. When incubated at 37°C in ambient air, isolates grew more rapidly on buffered charcoal yeast extract (BCYE) agar (visible after 24 h) than on SBA and chocolate agar (visible after 48 h) but failed to Partial 16S sequencing was performed as previously described, and sequences were interpreted according to CLSI guidelines (6, 9) . Sequences (JN986812 to JN986825) were aligned with those of thermoactinomycete type strains, and a phylogenetic tree ( Fig.  2A) was constructed using the neighbor-joining method in Molecular Evolutionary Genetics Analysis version 4.1 (11) . Sequences showed 100% similarity to the K. eburnea type strain (FN665656) when considering corresponding bases a match to IUPAC ambiguity symbols (i.e., "G" or "A" for "R").
Single bacterial colonies subcultured on SBA were analyzed on a microflex LRF MALDI-TOF mass spectrometer (Bruker Daltonics) in linear positive-ion mode using FlexControl 3.0 software (Bruker Daltonics) as reported elsewhere (7). A clinical isolate and the type strain of the closely related Desmospora activa species ( Fig.  2A ; AM940019) were included for comparison (14) . Isolates could be readily identified as K. eburnea and differentiated from D. activa after addition of reference spectra for both organisms to the Biotyper database (version 3.0; Bruker Daltonics) (median score, 2.4; range, 2.0 to 2.7). Using principal component analysis, mass spectra of clinical isolates from K. eburnea (n ϭ 12) and D. activa (n ϭ 1) clustered with the respective type strains (Biotyper version 3.0; Fig. 2B and C) .
The antimicrobial susceptibility of 11 clinical isolates was tested against a panel of 14 antimicrobial drugs. Individual colonies grown on SBA were incubated in Middlebrook 7H9 broth containing 3-mm-diameter glass beads at 37°C for 48 h and mixed every 8 to 12 h by vortexing. Suspensions were adjusted to a tur- bidity of 1.0 McFarland, 70 l was inoculated into 11 ml of cationadjusted Mueller-Hinton broth, and 100 l of the resulting dilutions was inoculated into each well of microtiter plates with lyophilized antimicrobials (Sensititre Rapid Growing Mycobacteria Plate [RAPMYCO]; Trek Diagnostic Systems). Plates were incubated at 37°C for 72 h and read according to CLSI guidelines for aerobic actinomycetes (13) . MICs were within Ϯ1 dilution for all isolates and were generally low, with the notable exception of clarithromycin (Ն32 g/ml; Table 2 ).
We recently reviewed 16S sequences of clinical isolates that belonged to as-yet-undescribed bacterial taxa (8) . Among these were 12 of the 14 isolates presented here, which could retrospectively be identified as K. eburnea. Two additional isolates were subsequently identified. Members of the Thermoactinomycetaceae are rarely isolated from patient specimens and are difficult to identify by conventional phenotypic testing. Their recognition has been facilitated by molecular identification methods, and several novel species have recently been described (1, 2, 5, 12, 14, 15) . Here we showed that K. eburnea has been repeatedly isolated from clinical specimens in different geographic regions of the United States. Isolates were readily identified by 16S sequencing and MALDI-TOF mass spectrometry.
Of the 14 isolates, 13 (93%) were recovered from normally sterile body sites (blood, CSF, peritoneal fluid), thus warranting definitive identification. Limited medical histories were available for only 3 patients. Repeated blood cultures in the 2 cases with blood culture isolates failed to reisolate this organism, and antimicrobial treatment was not initiated for any of the 3 patients. Establishing the pathogenic role of the organism in these cases was beyond the scope of this study, and the pathogenic role of these isolates in the three cases presented is unclear.
Little is known about the environmental distribution of K. eburnea. It was first identified by surface sampling in an air grade C area of a contract manufacturing organization in Germany. K. eburnea 16S sequences do not appear as part of human microbiome sequencing surveys in GenBank (data not shown), suggesting that they are unlikely to be common commensals. Thus, their significance and origin in these clinical cases remain unclear. By providing information on isolation and rapid identification of K. eburnea, this report can facilitate its identification in clinical microbiology laboratories and help determine the environmental distribution and pathogenicity of this recently described organism. 
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